---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058706"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:03:24.331649+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eledon Q1 net loss $10.3M ($0.34/share); cash $42.9M; $50M private placement

## Summary
- Net loss of $10.3M ($0.34 diluted EPS) vs $10.8M loss ($0.75 EPS) in Q1 2023.
- Cash, cash equivalents & short-term investments $42.9M at quarter end, excluding $50M private placement.
- Completed oversubscribed $50M private placement at $2.37/share with institutional investors.
- First patient dosed in investigator-led islet cell transplant trial with tegoprubart for type 1 diabetes.
- Phase 2 BESTOW trial (tegoprubart vs tacrolimus) enrolled 12th participant; full enrollment expected end 2024.

## SEC filing metadata
- accession: 0000950170-24-058706
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017024058706/0000950170-24-058706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017024058706/eldn-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058706
- JSON: https://secwatch.observer/filing/0000950170-24-058706.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058706.txt

## Key facts
- Earnings Releases
  Eledon Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $10.3 million, EPS $0.34 per share.
  - Period: the quarter ended March 31, 2024
  - Net income: net loss of $10.3 million
  - EPS: $0.34 per share
  - Result: reported results
  source text: The Company reported a net loss of $10.3 million, or $0.34 per share, for the three months ended March 31, 2024, compared to a net loss of $10.8 million, or $0.75 per share, for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017024058706/0000950170-24-058706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.